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Abstract
Background: Polygonum chinense Linn. is a common medicinal plant in Southeast Asia and has been used in
traditional medicine in Vietnam. The plant contains phytochemicals with various biological properties; however, its
antiviral effect has not yet been demonstrated. This study was aimed to evaluate the anti-influenza virus activity of
crude extracts of P. chinense, to characterize antiviral metabolites therefrom and to investigate their mechanisms of
antiviral action.
Methods: The methanol (MeOH) extract and organic solvent layers of P. chinense were prepared by extraction and
partition with relevant solvents. The ethyl acetate (EtOAc) layer showing antiviral activity was chromatographed
repeatedly on SiO2 and Sephadex LH-20 columns to give eight pure metabolites. Their chemical structures were
determined by NMR and MS spectral data. Anti-influenza virus activity of the eight metabolites against virus strains
A/Puerto Rico/8/34 (H1N1, PR8), A/Hong Kong/8/68 (H3N2, HK) and B/Lee/40 (Lee) was evaluated on the basis of
cytopathic effect (CPE) and plaque inhibition assays. Time-of-addition, confocal microscopy and neuraminidase
inhibition assay were performed for mode-of-action studies of active ingredients.
Results: The MeOH extract of P. chinense showed anti-influenza virus activity with EC50 values ranging from 38.4 to
55.5 μg/mL in a CPE inhibition assay. Among the eight pure metabolites isolated from P. chinense, ellagic acid (PC5)
, methyl gallate (PC7) and caffeic acid (PC8) significantly inhibited viral replication in a dose-dependent manner in
both plaque inhibition and CPE inhibition assays with EC50 values ranging from 14.7 to 81.1 μg/mL and CC50 values
higher than 300 μg/mL. Mode-of-action studies suggested that PC5 and PC7 suppress virus entry into or replication
in cells, while PC8 targets influenza viral neuraminidase, even oseltamivir-resistant one.
Conclusion: These results demonstrated that P. chinense and its metabolites possess effective anti-influenza virus
activities. The botanical materials of P. chinense could be a promising multitargeted inhibitor of influenza A and B
viruses and applied to development of a novel herbal medicine.
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Background
Influenza virus is an enveloped virus with negative-
strand, eight-segmented RNA genomes, belonging to the
Orthomyxoviridae family. Each viral segment is encapsi-
dated by a virus-encoded nucleoprotein (NP), called viral
ribonucleoprotein (vRNP) [1]. Influenza virions are pleo-
morphic, roughly spheroidal and approximately 100 nm
in diameter [2]. The viral envelope is distinguished by a
lipid bilayer containing three transmembrane protein-
s—hemagglutinin (HA), neuraminidase (NA), and matrix
protein 2 (M2, ion channel) on the outside and matrix
protein 1 (M1) beneath the membrane. The virus causes
pandemics and annual influenza epidemics. Influenza
outbreaks result in morbidity and mortality in the hu-
man population and commonly occur during winter, or
the rainy season in tropical countries [3, 4].
Pharmaceutical ingredients can be classified into two
groups: NA inhibitors, such as oseltamivir and zanami-
vir, and M2 inhibitors, such as amantadine and rimanta-
dine. These have been approved and used to treat and
prevent influenza infections. The NA inhibitors are ef-
fective against both influenza A and B viruses, while the
M2 inhibitors are effective only against influenza A virus
[5]. However, long-term use of these drugs is limited by
their toxicity and emergence of resistance [6]. Therefore,
the development of new, low-toxic anti-influenza viral
drugs is required.
Polygonum chinense (P. chinense) Linn. belonging to
the family Polygonaceae is a common medicinal plant
found in China, India, Japan and Southeast Asian coun-
tries. In Vietnam, the plant is widespread nationwide,
especially in open forest and highland [7]. This plant
has been used in traditional medicine for skin infec-
tious diseases such as eczema and zona, indigestion,
gastroenteritis and hepatitis, as well as for healing
inflammatory wounds or insect stings and snakebites
[7, 8]. Several phytochemistry studies of P. chinense
have been revealed that the plant contains terpenoids,
alkaloids, flavonoids, tannins, steroids and glycosides
[8–10]. Aqueous leaf extract of P. chinense possesses
gastroprotective activity [11]. Its methanol (MeOH) ex-
tract showed antimicrobial, antioxidant and cytotoxic
activities in vitro [8, 12]. Ethanol extract and isolated
bioactive substances exerted antidiarrheal effects [13].
However, its antiviral potential has not been investi-
gated. During screening of plant extracts against
influenza viruses, we found that the methanol extract
of P. chinense exhibited antiviral activity. Therefore, the
objectives of this study were to examine the antiviral
activities of its crude extracts against influenza virus
strains A/Puerto Rico/8/34 (H1N1, PR8), A/Hong
Kong/8/68 (H3N2, HK) and B/Lee/40 (Lee), to isolate
and identify effective metabolites and to investigate
their mechanisms of action.
Methods
Chemicals and reagents.
Silica gel 60 Å grade (particle sizes 15–40 μm and 40–
63 μm) for column chromatography was purchased
from Merck (Darmstadt, Germany). Sephadex LH-20
beads (size 25–100 μm) were purchased from Sigma-
Aldrich (St Louis, MO). Thin-layer chromatography
(TLC) plates (silica gel 60 F254, thickness 0.2 mm)
were obtained from Merck. Chemical spots on TLC
plates after development were detected using p-anisal-
dehyde-sulfuric acid (AS) and ferric chloride staining
reagents, together with I2 vapor. All solvents were dis-
tillated and purified before use.
Plant material
P. chinense samples were collected at Nhu Xuan in
Thanh Hoa province, Vietnam. Whole plant was dried in
the darkness and ground before extraction. Plant species
were identified by Dr. Tran The Bach (Institute of Ecol-
ogy and Biological Resources, Vietnam). A voucher spe-
cimen of the plant (No TL-CNHD.ĐT.048/13–15) was
deposited in the R&D Center of Bioactive Compounds,
Vietnam Institute of Industrial Chemistry, Vietnam.
Extract preparation and isolation of pure compounds
Dried and powdered P. chinense (10 kg) was extracted
with MeOH at room temperature and concentrated
to dryness in a rotary evaporator under reduced pres-
sure at below 40 °C. The MeOH extract (224 g) was
suspended in 2 L of distillated water and consecu-
tively partitioned with equal volumes of ethyl acetate
(EtOAc) and butanol (BuOH).
The EtOAc layer (95.2 g) was separated on a Sephadex
LH-20 (130 g, 70–100 μm, Sigma-Aldrich; 3.0 cm × 70 cm)
with MeOH eluent. The fractions that showed similar
TLC patterns were combined to yield more homogenous
samples, Frs. 1 to 9. Fr. 2 (13.6 g) which contains a main
component at Rf 0.83 on TLC (developed with EtOAc:-
MeOH 20:1 and showing a positive reaction with ferric
chloride stain) was separated on a silica gel column
[146 g silica gel 60 Å (40–63 μm), 3.4 × 40 cm] and was
eluted with a dichloromethane (DCM)-acetone stepwise
gradient (100: 1 to 100% acetone), yielding additional 12
fractions, Frs. 21 to 212. Fr. 26 contained a main com-
pound and was crystalized with acetone to give crystals
of PC1. Fr. 3 (7.2 g) was applied to a SiO2 column
[142 g silica gel 60 Å (40–63 μm), 3.4 × 40 cm, packed
with H:EtOAc (5:5, v/v)] and was eluted with a n-
Hexane (H): EtOAc stepwise gradient (5:5 to 1:9 and
EtOAc: MeOH 20:1 v/v, 500 mL each step) to produce
five fractions, Frs. 31 to 35. Fr. 33 was further chromato-
graphed on a silica gel column [SiO2 60 Å (15–40 μm),
2.0 × 45 cm] using DCM:MeOH (9:1, v/v) to give Fr. 34,
which contained crystals of compound PC3. Compound
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PC4 was isolated from Fr. 35 by chromatography using
silica gel [63 g, silica gel 60 Å (40–63 μm), 2.0 × 50 cm]
and eluting with a H:EtOAc stepwise gradient (7:3 to
1:9, v/v) and mixtures of EtOAc:MeOH (50:1, 30:1, 20:1
and 8:2, 7:3, v/v, 150 mL each step). Fr. 31 was also
isolated using a silica gel column [SiO2 60 Å (15–
40 μm), 2.0 × 45 cm] with a stepwise gradient elution of
H:EtOAc (10:1 to 3:7; 10% gradient and 100% EtOAc),
yielding compound PC7. A portion of Fr. 4 (1.23 g) was
subjected to column chromatography using a silica gel
column [37 g SiO2 60 Å (40–63 μm), 3.0 × 45 cm] with
eluting solvents of EtOAc: acetone (10:1, v/v, 200 mL)
and DCM:MeOH (20:1, v/v, 400 mL), yielding three frac-
tions, Frs. 41 to 43. PC2 was crystallized from the third
fraction, Fr. 43. Fr. 6 (20 g) was applied to a Sephadex
LH-20 column [100 g, 70–100 μm, Sigma-Aldrich;
2.2 × 60 cm] and eluted with MeOH to give five frac-
tions, Frs. 61–65. Fr. 63 was chromatographed using
silica gel and mixtures of E:MeOH (30: and 25:1) to fur-
nish PC8. Compound PC5 was purified from Fr. 5 (4 g)
using a Sep-pak C18 reverse-phase column and elution
with a water-MeOH mixture with a MeOH proportion
increasing from 70:30 to 100% MeOH.
A portion of Fr.1 (9.8 g) was separated on a silica gel
[100 g silica gel 60 Å (40–63 μm), 4.0 × 45 cm] column
and eluted using mixtures of H:acetone (98:2; 500 mL)
and DCM:MeOH (95:5; 400 mL) to give seven fractions,
Frs. 11 to 17. Frs. 13 and 14, which exhibited similar
TLC patterns, were pooled into Fr. 134 (2.6 g) and then
chromatographed on a silica gel column [70 g silica gel
60 Å (40–63 μm), 3.0 × 45 cm] with a mixture of H:acet-
one (8:2), yielding compound PC6.
Structure determination and characterization of the
isolated compounds
The chemical structures were determined by spectro-
scopic methods, including electrospray ionization (ESI)-
mass spectroscopy (MS) and nuclear magnetic resonance
(NMR) spectroscopy, and by comparison of their spectral
data with values reported previously [12, 16]. The ESI-MS
spectra of the purified compounds were recorded by LC-
MS (Agilent 1100 Series LC/MSD Trap XCT Plus, Agilent
Technologies, Palo Alto, CA). The 1H and 13C NMR,
COSY, HMQC and HMBC spectra were recorded in deu-
terated NMR solvents using a Bruker AMX-500 FT-NMR
spectrometer (Bruker Analytische Messtechnik Gmbh,
Rheinstetten, Germany).
PC1 (Quercetin): ESI-MS (positive) (m/z) 303 [M + H]+,
1H–NMR (500 MHz, DMSO-d6), δ (ppm): 6.183 (1H, d,
J = 2.0 Hz, H-6), 6.403 (1H, d, J = 2.0 Hz, H-8), 6.88 (1H, d,
J = 8.5 Hz, H-5′), 7.535 (1H, dd, J = 2.5, 8.5 Hz, H-8′), 7.67
(1H, d, J = 2.0 Hz, H-2′); 13C–NMR (125 MHz, DMSO-
d6), δ(ppm): 93.308 (C8), 98.138(C6), 102.976 (C10),
115.028(C2’), 116.2 (C5′), 119.938 (C6’), 121.917(C1′),
135.683 (C3), 145.016 (C3’), 146.774 (C2), 147.662 (C4’),
156.098 (C9), 160.682 (C5), 163.837 (C7), 175.8 (C4).
PC2 (Protocatechuic acid methyl ester): ESI-MS (nega-
tive) (m/z) 167.01 [M-H]−, 1H–NMR (500 MHz, acetone-
d6), δ (ppm): 3.801 (3H, s, −OCH3), 6.893 (1H, d,
J = 8.5 Hz, H-5); 7.435 (1H, dd, J = 2.0, 8.5 Hz, H-2), 7.493
(1H, d, J = 2.0 Hz, H-6); 13C–NMR (125 MHz, acetone-d6),
δ (ppm): 51.84 (−OCH3), 115.74 (C2), 117.14 (C5), 122.83
(C1), 123.26 (C6), 145.62 (C3), 150.77 (C4), 167.07 (COO).
PC3 (Gallic acid): ESI-MS (positive) (m/z) 339.0
[2 M–H]−, 193 [M + Na]+; 1H–NMR (500 MHz,
CD3OD-d4), δ (ppm): 7.076 (2H, s, H-2,6);
13C–NMR
(125 MHz, CD3OD -d4), δ (ppm): 110.32 (C2, 6), 122.02
(C1), 139.33 (C4), 146.38 (C3, 5), 170.49 (COOH).
PC4 (Quercitrin): The compound was identified as
quercetin 3-O-rhamnoside (also known as quercitrin)
by comparison with an authentic sample (Rf 0.54) on
a TLC plate using an E:A:M (40: 1:1, v/v/v) develop-
ing solvent and detected using the appropriate stains:
AS and ferric chloride.
PC5 (Ellagic acid): ESI-MS (positive) (m/z) 325[M + Na]+,
ESI-MS (negative) m/z 301 [M-H]−, 1H–NMR (125 MHz,
DMSO-d6), δ (ppm): 2.08–4.5 (s, −OH); 7.483 (2H, s, H-
5,5′); 13C–NMR (500 MHz, DMSO- d6), δ (ppm): 107.470
(C1,1’), 110.200 (C5,5’), 112.072 (C6,6′), 136.274 (C2, 2′),
139.377 (C3, 3′), 147.920 (C4, 4′), 158.728 (C7, 7′).
PC6 (β-Sitosterol): 1H–NMR (500 MHz, CDC13-d), δ
(ppm): 0.69 (3H, s, H-18), 0.803 (3H, d, J = 6.0 Hz, H-
27), 0.826 (3H, d, J = 4.0 Hz, H-26), 0.845 (3H, t,
J = 2.0 Hz, H-29), 0.925 (3H, d, J = 4.0 Hz, H-21), 1.008
(3H, s, H-19), 2.282–1.071 (28H, m), 2.305 (2H, m),
3.486 (1H, m, H-3), 5.347 (1H, brs, H-6); 13C–NMR
(125 MHz, CDC13-d), δ (ppm): 11.989 (C29), 12.215
(C24), 18.918 (C28), 19.180 (C19), 19.523 (C27), 19.945
(C26), 21.222 (C11), 23.215 (C23), 26.251 (C21), 28.376
(C16), 29.313 (C25), 31.779 (C2), 32.049 (C7), 32.049
(C8), 34.095 (C20), 36.279 (C18), 36.642(C10), 37.401
(C1), 39.923 (C12), 42.423 (C4), 42.460 (C13), 45.985
(C22), 50.286 (C9), 56.212 (C17), 56.911 (C14), 56.911
(C15), 71.908(C3), 121.817 (C6), 140.908(C5).
PC7 (Methyl gallate): ESI-MS (positive) m/z 185
[M + H]+, 1H–NMR (500 MHz, CD3OD-d6), δ (ppm):
3.825 (3H, s, −OCH3); 7.067 (2H, s, H-2, 6);
13C–NMR
(125 MHz, CD3OD-d6), δ (ppm): 52.250 (−OCH3);
110.044 (C2, 6), 121.449 (C1), 139.703 (C4), 146.441
(C3, 5), 169.007 (COO).
PC8 (Caffeic acid): 1H–NMR (500 MHz, CD3OD-d4),
δ (ppm): 6.24 (1H, d, J = 16 Hz, H-8), 6.80 (1H, d,
J = 8.5 Hz, H-5), 6.94 (1H, dd, J = 10.5 Hz, J = 2.0 Hz,
H-6), 7.06 (1H, d, J = 2.0 Hz, H-2), 7.55 (1H, d,
J = 15.5 Hz, H-7); 13C–NMR (125 MHz, CD3OD-d4), δ
(ppm): 115.104 (C2), 115.513 (C8), 116.488 (C5),
122.840 (C6), 127.803 (C1), 146.763 (C3), 147.038 (C7),
149.418 (C4), 171.022 (COOH).
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Cells, viruses and antiviral agents
Madin-Darby canine kidney (MDCK) cells and 293 T cells
were purchased from ATCC (Rockville, MD) and main-
tained in minimum essential medium (MEM; Invitrogen,
Carlsbad, CA) and in Dulbecco’s minimal essential
medium (DMEM; Invitrogen), respectively, supplemented
with 10% fetal bovine serum (FBS; Invitrogen) at 37 °C in
5% CO2. Influenza viruses PR8, HK and Lee were obtained
from ATCC. Influenza A viral strains (PR8 and HK) were
amplified by infection of 10-day-old chicken eggs at 37 °C
for 3 days and influenza B virus (Lee) by infection of
MDCK cells under serum-free conditions. Viruses were
partially purified from harvested egg allantoic fluid or cell
culture supernatant by centrifugation at 3000 rpm for
5 min. Viral titers were determined by HA assay or plaque
assay, and stocks were stored at −70 °C before use. Anti-
viral agents, ribavirin (RBV) (Sigma-Aldrich) and oselta-
mivir carboxylate (OSV-C; US Biological, Swampscott,
MA) were used as control compounds. The test extracts
and purified compounds, with the exception of the water
layer which was dissolved in water, were dissolved in
DMSO to 40 mg/mL and stored at −20 °C.
Rescue of PR8 virus with the H275Y mutation in NA
DNAs derived from eight-segmented PR8 genomic RNAs
were individually cloned into a vector harboring conver-
gent RNA polymerase I and II promoters using a universal
primer and genome-specific primers, generating pVP-PB2,
−PB1, −PA, −HA, −NP, −NA, −M and -NS [17–19]. Their
sequences were compared to those in GenBank (accession
numbers AB671295 for PB2, KC866596.1 for PB1, KC
866595.1 for PA, AB671289.1 for HA, KC866598.1 for NP,
CY033579.1 for NA, EF467824.1 for M and EF467817 for
NS, respectively). Using the plasmid pVP-NA, a histidin-
to-tyrosin mutation at amino acid 275 (H275Y) was intro-
duced with a primer (5′-GAATGCACCTAATTTTTACT
ACGAGGAATGTTC-3′: sequences corresponding to the
mutant tyrosin in bold) and its complementary one. The
QuickChange II Site-Directed Mutagenesis Kit (Stratagene,
LA Jolla, CA) were used to generate pVP-NA(H275Y). For
production of PR8 virus with the NA mutation H275Y
[rgPR8(H275Y)] by a reverse genetics system, 293 T cells
were co-trasfected with pVP-NA(H275Y) and the rest
seven pVP plasmids [17]. The rescued virus from the
culture supernatants was propagated into embryo-
nated chicken eggs and viral titer was determined as
mentioned above.
Cytopathic effect (CPE) inhibition assay
Cell viability was measured according to our previous
report [20]. In brief, MDCK cells were seeded in 96-well
plates and grown until 100% confluence. Cells were
mock-infected or infected with influenza virus at a
multiplicity of infection (MOI) of 0.001 for 1 h at 35 °C
under serum-free conditions. Unabsorbed virus was
removed by washing with PBS, and threefold serial
dilutions of compounds dissolved in MEM with 2 μg/
mL TPCK-trypsin were added to each well. On day 3
postinfection (p.i.), cell viability was measured using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT; Sigma-Aldrich). After reading the absorbance
at 540/690 nm, the half maximal cytotoxic concentration
(CC50) and the half maximal effective concentration
(EC50) were calculated using GraphPad Prism 6 (Graph-
Pad Software, La Jolla, CA). The selectivity index (S.I.) is
the ratio of CC50 to EC50.
Plaque inhibition assay
MDCK cells seeded in 48-well plates were infected with
the influenza viruses at an MOI of 0.001 for 1 h at 33 °C
(PR8) or 35 °C (HK and Lee). Test compounds and refer-
ence antiviral compounds were serially diluted in overlay
medium [MEM containing 0.5% carboxymethylcellulose
(CMC; Sigma) and 2 μg/mL TPCK-trypsin]. After washing
with PBS, the cells were treated with the compounds in
the overlay medium for 3 days at the temperature used for
virus infection. Viral plaques were counted by staining
with crystal violet [20].
Time-of-addition
To determine when the purified materials, PC5, PC7
and PC8, express their anti-influenza viral activity,
MDCK cells were treated with increasing concentrations
(from 4 to 100 μM) of each compound for 2 h before
(pre-treatment), during (co-treatment) or after (post-
treatment) PR8 infection [40 plaque forming units (PFU)
per well in 48-well plates] at 37 °C. After washing with
PBS, cells were incubated with overlay medium for 3 days
at 33 °C and stained with crystal violet to count the
number of viral plaques.
Confocal microscopy
Confluently grown MDCK cells in 4-well slides were in-
fected with the influenza viruses at an MOI of 1 for 4 h in
the presence either of 1 mM PC5, PC7 or PC8, or of
10 μM epigallocatechin gallate (EGCG), which was used
as a control to block viral entry [19]. After fixation and
permeabilization, cells were blocked with 10% goat serum
and 1% bovine serum albumin (BSA; Sigma-Aldrich) in
PBS. Viral NP was detected with mouse anti-NP antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) and Alex
Fluor 488-conjugated goat anti-mouse IgG (Invitrogen).
Nuclei were stained with DAPI (Vector Laboratories,
Burlingame, CA) according to the manufacturer’s
instructions.
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NA inhibition assay
Twenty-five microliters of PR8 or rgPR8(H275Y)
(2 × 105 PFU/mL) in PBS were mixed with an equal
volume of 3-fold serially diluted PC5, PC7, PC8 (from
6 mM to 80 μM) or OSV-C (from 60 to 0.8 nM) in PBS
in 96-well plates. After addition of 50 μL 200 μM NA-
fluor fluorescent substrate (Applied Biosystems, Foster
City, CA), the reaction was incubated at 37 °C for 1 h
and stopped with 100 μL of stop solution. The fluores-
cent intensity was measured with excitation at 350 nm
and emission at 450 nm.
Statistical analysis
Statistically significant differences were determined using
two-tailed Student’s t-test. P < 0.05 was considered
significant.
Results and discussion
Screening of antiviral activities in extracts from P. chinense
The anti-influenza viral activity of MeOH extract and
organic solvent layers from P. chinense was evaluated by
CPE inhibition assay. Cell viability was measured using
MTT to estimate the CC50 and EC50 values before and
after infection of MDCK cells with PR8, HK and Lee
(Table 1). As expected, OSV-C (an NA inhibitor) and
RBV (a viral polymerase inhibitor) efficiently inhibited
the replication of all viral strains tested, confirming the
reliability of the assay. MeOH extract of P. chinense
showed moderate inhibition of influenza viruses: EC50
values were 55.0 μg/mL for PR8, 38.8 μg/mL for HK and
55.5 μg/mL for Lee. The EtOAc layer derived from the
MeOH extract by liquid-liquid partitioning exhibited
EC50 values of 46.9, 23.2 and 50.8 μm/mL, respectively.
Moreover, the MeOH extract and EtOAc layer were not
cytotoxic to MDCK cells at the highest concentration
used, 300.0 μg/mL. The BuOH layer also displayed anti-
viral efficacy similar to EtOAc layer. However, the aque-
ous layer showed limited or no activity.
Isolation and identification of substances from P. chinense
Using repeated chromatographic processes, eight sub-
stances, PC1 to PC8, were further isolated from the
EtOAc layer (Fig. 1). Compound PC1 was purified as yel-
low crystals from Fr. 2. The ESI-MS (positive) spectrum of
PC1 showed a pseudo-molecular ion peak [M + H]+ at m/
z 303; this suggested it to have a molecular formula of
C15H10O7. The 1D–NMR spectrum of PC1 showed five
1H–NMR peaks, presenting aromatic proton signals in the
down-field region and 15 carbon signals with characteris-
tics of a C6-C3-C6 structure in the 13C–NMR spectrum.
By comparison of the 1D–NMR data of PC1 with those in
the literature, PC1 was identified as quercetin [15].
Compounds PC2, PC3, PC5 and PC7 were deter-
mined from their 13C–NMR spectra as derivatives of
gallic acid with six aromatic carbon signals and a car-
bonyl group. The molecular weight and formula of PC3
were determined to be 170 and C7H6O5, respectively
(339.0 [2 M–H]−in ESI-MS-negative; 193 [M + Na]+ in
ESI-MS-positive). Compound PC3 was identical to gallic
acid on the basis of 1D–NMR data analysis and com-
parison with those in the literature [16]. Compound
PC7 was identified as methyl gallate, which has a mo-
lecular formula of C8H8O5 (m/z 185 [M + H]
+ in ESI-
MS) and showed patterns of proton and carbon signals
similar to those of gallic acid (PC3), with the exception of
signals at 3.825 ppm (3H, s, −OCH3) in
1H–NMR and
52.250 ppm (−OCH3) in
13C–NMR, suggesting a methoxy
group. Compound PC2 was identical to protocatechuic
acid methyl ester, and was obtained as white crystals. Its
molecular formula was deduced to be C8H8O4 from a [M-
H]− pseudo-molecular ion peak at m/z 167.01 in ESI-MS.
The 13C–NMR spectrum of PC2 was similar to that of
PC7; it also revealed the presence of eight carbon signals,
comprising a carbonyl group at 167.07 ppm, a methoxy at
51.84 ppm and six aromatic carbons from 115.74 to
150.77 ppm including three methine groups at 115.74,
117.14 and 123.26 ppm. In comparison with the 1H–NMR
data of PC7, PC2 revealed a further two aromatic
methines. Moreover, the 1H–NMR spectrum of PC2





MeOH extract > 300.0 55.0 (> 5.5) 38.4 (> 7.8) 55.5 (> 5.4) μg/mL
Water layer > 300.0 175.8 (>1.7) 68.5 (> 4.4) 212.1 (> 1.4) μg/mL
BuOH layer > 300.0 45.9 (> 6.5) 18.3 (> 16.4) 70.1 (> 4.3) μg/mL
EtOAc layer > 300.0 46.9 (> 6.4) 23.2 (> 13.0) 50.8 (> 5.9) μg/mL
OSV-Cg > 100.0 0.38 (> 263.2) 0.005 (> 20,000) 1.2 (> 83.3) μM
RBVh > 100.0 49.9 (> 2.0) 20.5 (> 4.9) 26.6 (>3.8) μM
aCC50, 50% cell toxicity concentration;
bEC50, 50% effective concentration;
cS.I., selectivity index = CC50/EC50;
dPR8, A/Puerto Rico/8/34 (H1N1); eHK, A/Hong Kong/8/
68 (H3N2); fLee, B/Lee/40; gOSV-C, oseltamivir carboxylate; hRBV, ribavirin
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presented three aromatic protons at 7.435 (1H, dd, J = 2.0,
8.5 Hz, H-2), 6.893 (1H, d, J = 8.5 Hz, H-5), 7.493 (1H,d,
J = 2.0 Hz, H-6), and a methoxy group at 3.801 (3H, s,
−OCH3), which corresponds to a methyl ester bond based
on a cross-peak at 3.801 ppm and 167.07 ppm in HMBC.
PC5 was identified as ellagic acid and was obtained as an
amorphous solid with the structural formula C14H6O8
based on pseudo-molecular ion peaks at m/z 325
[M + Na]+ in ESI-MS (positive mode) and m/z 301 [M-
H]− in ESI-MS (negative mode). The chemical structure of
PC5 was determined by comparison with 1H- and 13C–
NMR data published previously [12].
Compound PC8 was purified from Fr. 6 as an amorph-
ous solid. Its chemical structure was identical to that of
caffeic acid on the basis of 1H- and 13C–NMR data ana-
lysis and comparison of these data with those in the litera-
ture [13]. Compounds PC4 and PC6 were identified by
comparing their Rf values with those of authentic
compounds that were spotted and developed on the same
TLC. PC4 was identified as quercitrin (quercetin 3-
rhamnoside) and contained a minor gallic acid impurity.
Therefore, this compound was not tested in our bioassays.
The 1H- and 13C–NMR spectra of PC6 were compared
with those reported previously [14]. Among eight com-
pounds isolated from P. chinense, PC6 was identified as β-
sitosterol, while the others were related to flavonoid
and phenolic metabolites found commonly in the
Polygonaceae family [10, 13, 15]. All PC compounds,
except for PC4, have been reported to possess anti-
fungal, antioxidant and other pharmaceutical proper-
ties [13, 16]. In this study, it was aimed to investigate
anti-influenza virus activities of the P. chinense con-
stituents systematically and their mode-of-action.
Anti-influenza virus activity of isolated compounds
To study the in vitro anti-influenza virus effects of
the isolated substances, CPE inhibition assay was per-
formed (Table 2 and Fig. 2). As reported in previous
Fig. 1 Chemical structures of substances isolated from P. chinense. PC1: quercetin; PC2: protocatechuic acid methyl ester; PC3: gallic acid; PC4:
quercitrin; PC5: ellagic acid; PC6: β-sitosterol; PC7: methyl gallate; and PC8: caffeic acid





PC1 quercetin > 300.0 12.6 (> 23.8) 13.1 (> 22.9) 15.0 (> 20.0) μg/mL
PC2 protocatechuic acid methyl ester 24.1 > 24.1 (N.A.g) > 24.1 (N.A.) 11.1 (2.2) μg/mL
PC3 gallic acid 111.1 20.8 (5.3) 17.5 (6.3) 24.5 (4.5) μg/mL
PC5 ellagic acid > 300.0 81.1 (> 3.7) 62.4 (> 4.8) 79.2 (> 3.8) μg/mL
PC6 β-sitosterol 300.0 281.6 (1.1) 300.0 (1.0) > 300.0 (N.A.) μg/mL
PC7 methyl gallate > 300.0 18.1 (> 16.6) 17.1 (> 17.5) 19.2 (> 15.6) μg/mL
PC8 caffeic acid > 300.0 37.8 (> 7.9) 32.1 (> 9.4) 14.7 (> 20.4) μg/mL
RBVh - > 100.0 21.7 (> 4.6) 15.5 (> 6.5) 17.0 (> 5.9) μM
OSV-Ci - > 100.0 0.07 (> 1428) < 0.005 (> 20,000) 0.21 (> 476) μM
aCC50, 50% cell toxicity concentration;
bEC50, 50% effective concentration;
cS.I., selectivity index = CC50/EC50;
dPR8, A/Puerto Rico/8/34 (H1N1); eHK, A/Hong Kong/8/
68 (H3N2); fLee, B/Lee/40; gN.A. not applicable; hOSV-C oseltamivir carboxylate; iRBV ribavirin
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studies [21, 22], PC1 showed anti-influenza A virus
activity with an EC50 of 12.6 μg/mL and 13.1 μg/mL
for PR8 and HK, respectively, without cytotoxicity at
300 μg/mL (Table 2). This result was in agreement
with the report by Wu et al. [22], in which quercetin
revealed broad-spectrum inhibitory activity against in-
fluenza A viruses such as PR8, A/FM-1/47/1 (H1N1)
and A/Aichi/2/68 (H3N2) by interaction with the viral
HA2 subunit. However, in our study, the compound
induced overgrowth of uninfected MDCK cells, result-
ing in 150–160% increases in cell viability at 100 and
300 μg/mL (Fig. 2). This undesirably increased optical
density was likely not due to the colorimetric properties of
PC1, as it was not detected in MTT-based viability tests
of other cells, such as Vero (African green monkey kidney
cell line), MT4 (human T-cell line) or HuT 78 (human T-
cell lymphoma cell line), in the presence of PC1 (data not
shown). It was expected that PC1 non-specifically stimu-
lated cell viability of MDCK cells. PC6 displayed marginal
or no anti-influenza activity and cytotoxicity to MDCK
cells, with a CC50 value of 300 μg/mL (Table 2 and Fig. 2).
Accordingly, PC1 and PC6 were excluded from further
antiviral assays.
Compounds PC2, PC3, PC5 and PC7 are gallic acid
and its derivatives (Fig. 1), all of which, except for PC2,
exhibited activity against influenza A and B strains
(Table 2). In terms of selectivity, PC7 showed the most
desirable antiviral profile with EC50 values of 18.1, 17.1
and 19.2 μg/mL against PR8, HK and Lee, respectively.
However, it also contained latent cytotoxicity, reducing
cell viability by 49% at the maximum concentration,
300 μg/mL (Fig. 2). The inhibition of PR8 by PC7 was
Fig. 2 Dose response curves of PC1 to PC3 and PC5 to PC8 isolated from P. chinense against PR8, HK and Lee and the MDCK host cell line. Cell
monolayers were mock-infected or infected with influenza A and B viruses at a MOI of 0.001 for 1 h. After washing with PBS, compounds serially
diluted in MEM with 2 μg/mL TPCK-trypsin were added to the wells and incubated for 3 days. Cell viability was measured by MTT assay. RBV was
used as a positive control. The values are means ± standard deviation (SD) from three replicates
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described in a previous report [23]. Nevertheless, it is
noteworthy that this may be the first report of the anti-
influenza activity of methyl gallate (PC7) against
additional strains A/H3N2 and B. Consistent with other
researchers’ observation [21, 24], we found that gallic
acid (PC3) and ellagic acid (PC5) are active against in-
fluenza viruses, even though PC3 showed cytotoxicity
with CC50 of 111.1 μg/mL (Table 2). The anti-influenza
viral activity of gallic acid and its derivatives as well as
quercetin could be associated with their planar structure
and cell membrane permeability, as described previ-
ously [21]. The last compound, PC8 showed desirable
antiviral activity with EC50 values ranging from 14.7
to 37.8 μg/mL without cytotoxicity or an abnormally
increase in cell viability at the maximum concentra-
tion treated (300.0 μg/mL) (Table 2 and Fig. 2).
The antiviral activity of the three most effective com-
pounds, PC5, PC7 and PC8, was compared by plaque in-
hibition assay, a standard method for measuring the
activity of viral inhibitors. Consistent with results from the
CPE assay (Table 2), they inhibited plaque formation of
influenza A and B viruses in a dose-dependent manner
(Fig. 3). Our findings suggest that among the three com-
pounds, PC8 has the greatest antiviral efficacy and lowest
cytotoxicity. Even though PC5 suppressed plaque forma-
tion significantly at all concentrations tested (P < 0.05), it
was less potent than PC7 and PC8 (Fig. 3a). PC7
showed potent antiviral activity with relatively high
S.I. values (Table 2), but it seemed to have marginal
cytotoxicity given that crystal violet staining resulted
in faint background images at concentrations higher
than 33 μg/mL (Fig. 3b). This observation was in
agreement with the CPE assay graph (compare Figs. 2
and 3), confirming the reliability of the cell culture-
based antiviral screening system. The antiviral activity
of caffeic acid (PC8) against influenza A virus, includ-
ing H1N1 and H3N2 strains, was reported previously
[25]. Herein, we evaluated the spectrum of its efficacy
also against influenza B virus (Fig. 3c).
Mode-of-action of PC5, PC7 and PC8
Although anti-influenza viral activity of ellagic acid (PC5),
methyl gallate (PC7) and caffeic acid (PC8) in vitro or in
vivo was presented in several previous reports [23, 25, 26],
their mechanisms of action have not yet been elucidated
clearly except for PC8, that targets viral NA protein [27].
To investigate their effects on virus entry and early repli-
cation in cells, time-of-addition experiment was per-
formed (Fig. 4). Treatment of PC5 for 2 h before (pre-
treatment) or after (post-treatment) reduced viral plaque
titers, while plaque reduction was more distinct when it
was treated during virus infection (co-treatment) (Fig. 4a).
It means that PC5 could affect both viral and cellular
factors working at early steps of the virus life cycle and
potentially interfere with their interaction. PC7 also
showed the most significant antiviral activity when it was
co-treated, resulting in about 35% reduction (Fig. 4b). It
marginally reduced the viral infectivity by 15% at the
Fig. 3 Plaque inhibition assay of PC5 (a), PC7 (b) and PC8 (c) against PR8, HK and Lee. At 1 h after infection with influenza virus at an MOI of
0.001, MDCK cells were treated with serially diluted compounds dissolved in the overlay medium. At day 3 postinfection, viral plaques were
visualized using crystal violet staining. The images are representative of three experiments (upper). The numbers of plaques in each well were
counted (lower). Shown are averaged percentages and SD of three different wells. n.d., not detected. *P < 0.05
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maximum concentration (100 μM) in the post-treatment
experiment, while no inhibition when treated before virus
infection. It is expected that PC7 might regulate a host
factor essential for influenza virus entry or early replica-
tion. PC8 resulted in no significant antiviral activity when
treated before or after virus infection, but its co-treatment
barely showed the efficacy at the maximum concentration
(Fig. 4c). It can be suggested that PC8 is partially involved
in suppression of the influenza virus entry step. To ensure
that PC5 and PC7 suppress influenza virus entry or early
replication, we analyzed viral NP protein production in
cells by confocal microscopy (Fig. 5). Here, the 4-h incu-
bation of influenza A virus PR8 was optimized for nuclear
localization of NP. The result clearly showed that both
PC5 and PC7 inhibit the early steps similar to EGCG,
which is a virus entry blocker [20]. As expected, PC8 did
not affect NP signal intensity or its localization within 4 h
after virus infection.
To further examine whether PC8, known as an NA in-
hibitor [27], targets not only wild-type NA protein but
also its OSV-C-resistant one, fluorescence NA inhibition
assay was performed using live influenza viruses, PR8 and
rgPR8(H275Y) (Fig. 6). Although NA inhibitory effect of
PC8 against PR8 was less potent than that of OSV-C, it
showed consistent activity against rgPR8(H275Y), that is a
reverse genetically rescued virus resistant to OSV-C (com-
pare panels A and B in Fig. 6). It suggested that PC8 tar-
gets influenza virus NA protein as OSV-C does but
in a different binding manner. Moreover, previous re-
ports proposed that the NA activity is involved in in-
fluenza virus entry as well as release of progeny virus
[28]. Thus, it can be explained the reason for mar-
ginal inhibition of the initial stage of PR8 infection by
the NA inhibitor, PC8 (Fig. 4c).
Conclusion
The present study is the first report on anti-influenza
virus activity of P. chinense and identification of the ac-
tive components. MeOH extract, EtOAc and BuOH
layers of the plant were active against influenza viruses
A B C
Fig. 4 Time-of-addition of the PC compounds. Mock (0.1% DMSO) or increasing concentrations of PC5 (a), PC7 (b) or PC8 (c) were applied to MDCK
cells for 2 h before (pre-treatment), during (co-treatment) or after (post-treatment) PR8 infection (40 PFU per well in 48-well plates) at 37 °C. Cells were
washed with PBS and additionally incubated under the overlay medium for 3 days at 33 °C. The number of plaques was counted after staining with
crystal violet. The values shown are the means ± S.D. of triplicate samples and expressed as a percentage relative to the plaque number with mock
solution in each experiment. *P < 0.05
Fig. 5 Confocal microscopy. MDCK cells were infected with PR8 virus at an MOI of 1 in the presence either of 1 mM PC5, PC7 or PC8 or of
10 μM EGCG (an entry blocker) at 37 °C for 4 h. The viral NP was labeled with mouse anti-NP antibody and Alexa Fluor 488-conjugated goat anti-
mouse antibody (green). Cellular nuclei were counterstained with DAPI (blue). Original magnification, 400 ×
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of A/H1N1, A/H3N2 and B. Among constituents isolated
from the EtOAc layer, ellagic acid, methyl gallate and
caffeic acid exhibited considerable inhibitory activity
against the pathogens. Based on the mode-of-action stud-
ies, ellagic acid and methyl gallate suppress the early steps
of the viral life cycle. In contrast caffeic acid targets the
NA protein, comparably suppressing both wild-type and
OSV-C-resistant influenza viruses. Our study suggests that
the multi-functional botanical materials of P. chinense
could be promising inhibitors of influenza A and B viruses
and applied to development of a novel herbal medicine.
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